LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Thursday, June 26, 2025

April 11, 2025 | Last Trade: US$2.75 0.04 1.48

SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing or direct patient care services segments, today announced that its Annual Meeting of Shareholders will be held on Thursday, June 26, 2025, at 9:00 a.m. CT.

The Annual Meeting will be an in-person meeting. For those who wish to attend, the meeting will be held at 3041 Woodcreek Drive, #200, Downers Grove, IL 60515. The Board of Directors fixed the close of business on April 28, 2025, as the record date for determination of shareholders entitled to notice of and to vote at the Annual Meeting.

About American Shared Hospital Services (NYSE American: AMS)

American Shared Hospital Services (AMS) is a leading provider of turnkey solutions to cancer treatment centers, health systems, and cancer networks in North and South America. The company works closely with its partners to develop and grow their cancer service lines and provide integrated cancer care to patients in a convenient local setting close to home. For centers under health system partnerships, the Company and its health system partners share in the capital investment cost and profitability of the operations based on their respective ownership interests. For more information, please visit: www.ashs.com

Contacts
American Shared Hospital Services
Ray Stachowiak, Executive Chairman
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations
Kirin Smith, President
PCG Advisory, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page